MONALEESA-2: improved OS seen in HR+ advanced breast cancer treated with ribociclib + letrozole

MONALEESA-2: ribociclib + letrozole in pts with de novo metastatic disease and late recurrenceПодробнее

MONALEESA-3 OS results: fulvestrant/ribociclib in postmenopausal HR+/HER2- advanced breast cancerПодробнее

GS2-01: "Overall survival subgroup analysis by metastatic site from the phase3 MONALEESA-2..."Подробнее

QOL in MONALEESA-2, 3, and 7Подробнее

Safety and efficacy of ribociclib and letrozole in advanced breast cancer – the MONALEESA-2 trialПодробнее

Updated Results of the MONALEESA-2 Trial in HR+/HER2- Breast CancerПодробнее

Overall survival results from MONALEESA-2: Endocrine therapy and ribociclib in HR positive and H...Подробнее

Dr. Burris on Updated MONALEESA-2 Trial Results for HR+ Breast CancerПодробнее

HR–positive advanced breast cancer: Ribociclib improved PFS for pre and perimenopausal womenПодробнее

Early RIBECCA results: ribociclib with letrozole for metastatic breast cancerПодробнее

ESMO 2016: Press brief on the MONALEESA-2 clinical trial on breast cancerПодробнее

Dr. Hortobagyi on MONALEESA-2 Trial Results in Breast CancerПодробнее

Results of the MONALEESA-2 Study in Advanced Breast CancerПодробнее

Gabriel Hortobagyi:Подробнее

Frontline endocrine therapies and ribociclib in early stage HR+ HER2- breast cancerПодробнее

Adding ribociclib to endocrine therapy shows an improvement in invasive DFS in HR+/HER2 BC patientsПодробнее

Ribociclib in adjuvant HR+ breast cancerПодробнее

Overall survival results from MONALEESA-3 study on ribociclib plus fulvestrant in advanced breas...Подробнее

FDA Approval of Ribociclib for Metastatic Breast CancerПодробнее